AbCellera FY2021 revenue $375M (+61% YoY); EPS $0.56; 26 new program starts

AbCellera Biologics Inc.

2021-FY EPS reported $0.48 revenue$375,203,000

Total revenue $375.2M (up 61% from $233.2M in 2020), driven by $327.3M in royalty revenue.
Net earnings $153.5M ($0.56 basic EPS) vs. $118.9M ($0.53) in 2020; diluted EPS $0.48.
Ended year with $723M in cash and marketable securities; 26 new program starts (78 cumulative).
Q4 revenue $139.3M (37% of FY total), net earnings $59.9M ($0.21 basic EPS).
Five molecules now in clinic (up from one); acquired TetraGenetics for transmembrane protein targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.